CA2791702C - The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas - Google Patents

The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas Download PDF

Info

Publication number
CA2791702C
CA2791702C CA2791702A CA2791702A CA2791702C CA 2791702 C CA2791702 C CA 2791702C CA 2791702 A CA2791702 A CA 2791702A CA 2791702 A CA2791702 A CA 2791702A CA 2791702 C CA2791702 C CA 2791702C
Authority
CA
Canada
Prior art keywords
fenoterol
tumor
compound
beta
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2791702A
Other languages
English (en)
French (fr)
Other versions
CA2791702A1 (en
Inventor
Irving W. Wainer
Michel Bernier
Lawrence Robert Toll
Lucita Arenas Jimenez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
US Department of Health and Human Services
Original Assignee
SRI International Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc, US Department of Health and Human Services filed Critical SRI International Inc
Publication of CA2791702A1 publication Critical patent/CA2791702A1/en
Application granted granted Critical
Publication of CA2791702C publication Critical patent/CA2791702C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2791702A 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas Active CA2791702C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31264210P 2010-03-10 2010-03-10
US61/312,642 2010-03-10
PCT/US2011/027988 WO2011112867A1 (en) 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Publications (2)

Publication Number Publication Date
CA2791702A1 CA2791702A1 (en) 2011-09-15
CA2791702C true CA2791702C (en) 2018-05-29

Family

ID=43858307

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2791702A Active CA2791702C (en) 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Country Status (7)

Country Link
US (4) US9492405B2 (enExample)
EP (1) EP2544676B1 (enExample)
JP (1) JP5837890B2 (enExample)
AU (2) AU2011224241B2 (enExample)
BR (1) BR112012022552A8 (enExample)
CA (1) CA2791702C (enExample)
WO (1) WO2011112867A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2854855B1 (en) 2012-05-25 2016-04-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
EP3125878A4 (en) * 2014-04-03 2017-11-29 Mitchell Woods Pharmaceuticals, Inc. Methods of treating breast cancer
EP3125877A4 (en) * 2014-04-03 2017-11-22 Mitchell Woods Pharmaceuticals, Inc. Methods of treating melanoma
KR101585619B1 (ko) * 2014-11-20 2016-01-15 주식회사 아모텍 감전보호소자 및 이를 구비한 휴대용 전자장치
WO2016144371A1 (en) * 2015-03-06 2016-09-15 Mitchell Woods Pharmaceuticals, Inc. Methods of treating cancer
US20180271808A1 (en) * 2015-10-01 2018-09-27 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
US20190337889A1 (en) * 2015-10-18 2019-11-07 Onco Therapies Llc Compositions and methods of regulating cancer related disorders and diseases
EP3490581A4 (en) * 2016-07-26 2020-10-14 Flagship Pioneering Innovations V, Inc. NEUROMODULATORY COMPOSITIONS AND ASSOCIATED CANCER TREATMENT METHODS
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN109942462B (zh) * 2019-03-06 2022-01-14 宏冠生物药业有限公司 一种盐酸班布特罗的合成工艺
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
CN114456078B (zh) * 2022-01-19 2022-09-16 汉瑞药业(荆门)有限公司 一种(r)-n-苄基-1-(4-甲氧基苯基)丙-2-胺的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL296701A (enExample)
SE354279B (enExample) 1969-06-13 1973-03-05 Draco Ab
DE1962497C3 (de) 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
CH564509A5 (enExample) 1969-12-12 1975-07-31 Boehringer Sohn Ingelheim
DE2010883A1 (de) 1970-03-07 1971-09-23 Troponwerke Dinklage & Co, 5000 Köln-Mülheim Pharmakologisch wirksame Aminoalkohole und Verfahren zu ihrer Darstellung
AT308139B (de) 1970-07-27 1973-06-25 Degussa Verfahren zur Herstellung von neuen basisch substituierten Alkyltheophyllinen, ihren Isomeren und Säureadditionssalzen
IT1044214B (it) 1971-04-22 1980-03-20 Zambeletti Spa L 2 idrossi 2 feniletilamine so stituite dotate di proprieta vasoattive e processo per la loro preparazione
JPS532194B2 (enExample) 1973-08-10 1978-01-26
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US6866839B2 (en) 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
DE69325454T2 (de) 1992-04-17 2000-01-20 Abbott Laboratories, Abbott Park Taxol-derivate
AU4408897A (en) 1996-07-05 1998-02-02 E.C. Pesterfield Associates, Inc. Method of treating retinal ischemia and glaucoma, using optically pure r- or rr- isomers of adrenergic beta-2 agonists
US6015837A (en) 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
WO1999016430A1 (en) 1997-09-30 1999-04-08 E.C. Pesterfield Associates, Inc. Galenic forms of r-or rr-isomers of adrenergic beta-2 agonists
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
WO2000018389A2 (en) 1998-09-30 2000-04-06 The United States Of America, Represented By The Secretary, Department Of Health And Human Services USE OF A β2 ADRENERGIC RECEPTOR AGONIST IN THE TREATMENT OF CARDIOVASCULAR DISEASE
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
EP1507754A1 (en) 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050107417A1 (en) 2003-07-28 2005-05-19 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a betamimetic
AU2004285961A1 (en) 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
CA2560538A1 (en) 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
WO2006015830A1 (en) 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
WO2006074897A1 (en) 2005-01-11 2006-07-20 Glaxo Group Limited Cinnamate salts of a beta-2 adrenergic agonist
EP2064174B1 (en) * 2006-08-10 2016-10-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Preparation of (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
EP2207537B1 (en) 2007-10-02 2017-06-14 Fremont Group Ltd Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alpha-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength
CN102740895B (zh) * 2009-12-23 2016-02-24 伊利诺伊大学董事会 纳米轭合物以及纳米轭合物配制品

Also Published As

Publication number Publication date
WO2011112867A1 (en) 2011-09-15
WO2011112867A8 (en) 2012-09-27
AU2014210656A1 (en) 2014-08-28
AU2014210656B2 (en) 2016-03-17
US20130005799A1 (en) 2013-01-03
US10130594B2 (en) 2018-11-20
AU2011224241B2 (en) 2014-05-08
BR112012022552A8 (pt) 2017-12-05
US10925840B2 (en) 2021-02-23
AU2011224241A1 (en) 2012-09-20
US10617654B2 (en) 2020-04-14
US9492405B2 (en) 2016-11-15
US20190008802A1 (en) 2019-01-10
JP5837890B2 (ja) 2015-12-24
BR112012022552A2 (pt) 2016-08-30
JP2013522230A (ja) 2013-06-13
CA2791702A1 (en) 2011-09-15
EP2544676A1 (en) 2013-01-16
US20200197332A1 (en) 2020-06-25
US20170007556A1 (en) 2017-01-12
EP2544676B1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
US10925840B2 (en) Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
CA2660707C (en) Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
CA2874655C (en) Methods of regulating cannabinoid receptor activity-related disorders and diseases
US20180042867A1 (en) Methods of treating cancer
WO2017059268A1 (en) Methods of reducing chemoresistance and treating cancer
US20170172945A1 (en) Methods of treating breast cancer
AU2013202127B2 (en) Preparation of (R,R-)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
WO2018140923A1 (en) Methods of treating cancer
EP3371181A1 (en) Compositions and methods of regulating cancer related disorders and diseases
AU2014224073A1 (en) Preparation of (R,R-)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
CA2944743A1 (en) Methods of treating melanoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151222

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250304

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250304